Why is Arrivent Biopharma stock collapsing today?
Arrivent Biopharma (AVBP) shares dropped 56.7% in pre-market trading after its Phase 3 FURVENT trial failed to meet the primary endpoint of progression-free survival for firmonertinib. The 240mg dose showed a median PFS of 11.0 months vs. 9.5 months for chemotherapy, but the hazard ratio was not statistically significant. CEO Bing Yao noted the disappointing results and the company is evaluating next steps.
How this was made
The 30-second read
Why it matters
The miss undermines the drug's path to FDA approval and erodes the company's valuation, reflected in a near‑60% pre‑open plunge.
Market read
The trial failure is a primary catalyst for AVBP's sharp price move and may influence sentiment across oncology biotech stocks.
What to watch
Potential for a revised dosing strategy or combination therapy could revive the asset's prospects.
Background
Arrivent Biopharma (AVBP) announced that its lead oncology candidate, firmonertinib, failed to achieve statistical significance for progression‑free survival in a pivotal Phase 3 trial.
Ticker impact
Arrivent Biopharma disclosed its Phase 3 FURVENT trial missed the primary endpoint, causing a 56.7% pre‑open drop.
downward pressure as investors price in the missed endpoint and delayed approval path
The primary endpoint miss is a material clinical setback; no mitigating data offset the negative sentiment, and the stock already fell sharply.
Market effects
Biotech sector may see broader risk aversion to early‑stage oncology trials.
US biotech stocks could experience modest pullback in early trading.
Limited to investors focused on clinical‑stage biotech exposures.
Counterpoint
If secondary endpoints hold promise, some investors may view the dip as a buying opportunity for a long‑term play.
Key entities
- companyArrivent Biopharma
Biopharma firm developing firmonertinib for EGFR exon 20 insertion‑mutant NSCLC.
- executiveBing Yao
CEO of Arrivent Biopharma, commented on the trial outcome.
